Head-to-head · WeighScore
altRX vs Primary Clinic (Direct GLP)
The verdict
altRX takes it — 71.4/100 to 68.7/100.
altRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. altRX is a dual-modality telehealth platform offering compounded GLP-1s plus all four brand-name FDA-approved options — Mounjaro, Ozempic, Wegovy, and Zepbound — the most comprehensive brand-name lineup in…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | altRX | Primary Clinic (Direct GLP) |
|---|---|---|
| WeighScore | 71.4/100 | 68.7/100 |
| Grade | C | C |
| Scorecard rank | #93 | #145 |
| Semaglutide | $149/mo (starting dose, compounded) | $65/mo (0.25 mg dose, promotional rate, compounded) |
| Tirzepatide | $249/mo (starting dose, compounded) | $110/mo (2.5 mg dose, promotional rate, compounded) |
| Coverage | Coverage not published | 10 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #93 · C
Strengths
- Offers all four brand-name FDA-approved GLP-1s (Mounjaro, Ozempic, Wegovy, Zepbound) — the most comprehensive brand-name access we've reviewed
- LegitScript Certified with a publicly verifiable seal
- Publishes the FDA compounded-medication disclaimer
- Transparent pricing across all six product tiers (compounded plus four brand-name)
- All-inclusive pricing — consult, prescription, and shipping with no hidden fees
Where it loses points
- States-served list not disclosed
- 503A/503B pharmacy partner not named (only 'multiple USA-certified pharmacies')
- 503A vs 503B designation not specified
- No named medical director
- Corporate physical address not disclosed
Graded #145 · C
Strengths
- Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
- GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
- Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
- Routine labs and thousands of medications included in membership — no surprise bills
- Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide
Where it loses points
- 10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
- Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
- 503A pharmacy partners not named
- LegitScript certification not mentioned on the site
- Medical director and corporate legal entity not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.